Event brochure is now live: Global Pharma and Biotech Summit returns to London
No images? Click here
Presented by
In collaboration with
November 10-11 | In-Person & Digital (London)
GLOBAL PHARMA AND BIOTECH SUMMIT
Save 10% as an Endpoints reader with code EP10
China's biotech boom is rewriting the dealmaking playbook.
Chinese biotechs signed 93 licensing deals with global pharma worth $85 billion in the first eight months of 2025. Their share of new drug candidates entering trials has climbed from 8% in 2018 to 30% in 2025.*
China, once a generics producer, has become a global innovation force, and for Western pharma, the question is no longer whether to engage but how: which partnerships to strike, how to judge Chinese trial data and what it takes to compete on speed and cost. What does the next chapter in global pharma power bring?
Save 10% as an Endpoints reader with code EP10
EVENT BROCHURE IS NOW LIVE
View confirmed speakers, the full agenda and who you can meet in person on November 10-11. Download the brochure now.
China's rise is the story every dealmaker, regulator and pipeline strategist is tracking.
The Global Pharma and Biotech Summit, presented by the Financial Times in collaboration with Endpoints News, puts China's rise firmly on the agenda. Dealmakers and industry leaders will map the next chapter: what makes partnerships with Chinese companies work, whether Europe moves closer to Beijing or risks being left behind, and what it will take for Chinese drugmakers to build global blockbusters. Join us in London or online, and get ahead of the story reshaping every pipeline conversation.
Save 10% as an Endpoints reader with code EP10
* Deal figures cover Jan.-Aug. 2025, from the Financial Times report "China's biotech boom," published June 2026.
In collaboration with
Global Knowledge Partner
Strategic Partner
Lead Sponsor
